BACKGROUND: Allergic airway inflammation contributes to the airway remodelling that has been linked to increased obstruction and morbidity in asthma. However, the mechanisms by which allergens contribute to airway remodelling in humans are not fully established. CCL18, chitotriosidase (CHIT1) and YKL-40 are readily detectable in the lungs and contribute to remodelling in other fibrotic diseases, but their involvement in allergic asthma is unclear. OBJECTIVE: We hypothesized that CCL18, YKL-40 and CHIT1 bioactivity are enhanced in allergic asthma subjects after segmental allergen challenge and are related to increased pro-fibrotic and Th2-associated mediators in the lungs. METHODS: Levels of CCL18 and YKL-40 protein and chitotriosidase (CHIT1) bioactivity in bronchoalveolar lavage (BAL) fluid, as well as CCL18, YKL-40 and CHIT1 mRNA levels in BAL cells were evaluated in patients with asthma at baseline and 48 h after segmental allergen challenge. We also examined the correlation between CCL18 and YKL-40 levels and CHIT1 activity with the levels of other pro-fibrotic factors and chemokines previously shown to be up-regulated after allergen challenge. RESULTS: Chitotriosidase activity and YKL-40 and CCL18 levels were elevated after segmental allergen challenge and these levels correlated with those of other pro-fibrotic factors, T cell chemokines, and inflammatory cells after allergen challenge. CCL18 and YKL-40 mRNA levels also increased in BAL cells after allergen challenge. CONCLUSIONS AND CLINICAL RELEVANCE: Our results suggest that CCL18 and YKL-40 levels and CHIT1 activity are enhanced in allergic airway inflammation and thus may contribute to airway remodelling in asthma.
BACKGROUND:Allergic airway inflammation contributes to the airway remodelling that has been linked to increased obstruction and morbidity in asthma. However, the mechanisms by which allergens contribute to airway remodelling in humans are not fully established. CCL18, chitotriosidase (CHIT1) and YKL-40 are readily detectable in the lungs and contribute to remodelling in other fibrotic diseases, but their involvement in allergic asthma is unclear. OBJECTIVE: We hypothesized that CCL18, YKL-40 and CHIT1 bioactivity are enhanced in allergic asthma subjects after segmental allergen challenge and are related to increased pro-fibrotic and Th2-associated mediators in the lungs. METHODS: Levels of CCL18 and YKL-40 protein and chitotriosidase (CHIT1) bioactivity in bronchoalveolar lavage (BAL) fluid, as well as CCL18, YKL-40 and CHIT1 mRNA levels in BAL cells were evaluated in patients with asthma at baseline and 48 h after segmental allergen challenge. We also examined the correlation between CCL18 and YKL-40 levels and CHIT1 activity with the levels of other pro-fibrotic factors and chemokines previously shown to be up-regulated after allergen challenge. RESULTS: Chitotriosidase activity and YKL-40 and CCL18 levels were elevated after segmental allergen challenge and these levels correlated with those of other pro-fibrotic factors, T cell chemokines, and inflammatory cells after allergen challenge. CCL18 and YKL-40 mRNA levels also increased in BAL cells after allergen challenge. CONCLUSIONS AND CLINICAL RELEVANCE: Our results suggest that CCL18 and YKL-40 levels and CHIT1 activity are enhanced in allergic airway inflammation and thus may contribute to airway remodelling in asthma.
Authors: Chun Geun Lee; Carla A Da Silva; Charles S Dela Cruz; Farida Ahangari; Bing Ma; Min-Jong Kang; Chuan-Hua He; Seyedtaghi Takyar; Jack A Elias Journal: Annu Rev Physiol Date: 2011 Impact factor: 19.318
Authors: A Pardo; K M Smith; J Abrams; R Coffman; M Bustos; T K McClanahan; J Grein; E E Murphy; A Zlotnik; M Selman Journal: J Leukoc Biol Date: 2001-10 Impact factor: 4.962
Authors: Frantisek Mrazek; Veronika Sekerova; Jiri Drabek; Vitezslav Kolek; Roland M du Bois; Martin Petrek Journal: Immunol Lett Date: 2002-10-21 Impact factor: 3.685
Authors: Lin Ying Liu; Julie B Sedgwick; Mary Ellen Bates; Rose F Vrtis; James E Gern; Hirohita Kita; Nizar N Jarjour; William W Busse; Elizabeth A B Kelly Journal: J Immunol Date: 2002-12-01 Impact factor: 5.422
Authors: Ichiro Nomura; Elena Goleva; Michael D Howell; Quatyba A Hamid; Peck Y Ong; Clifton F Hall; Marc A Darst; Bifeng Gao; Mark Boguniewicz; Jeffrey B Travers; Donald Y M Leung Journal: J Immunol Date: 2003-09-15 Impact factor: 5.422
Authors: Sergei P Atamas; Irina G Luzina; Jung Choi; Natalya Tsymbalyuk; Nicholas H Carbonetti; Ishwar S Singh; Maria Trojanowska; Sergio A Jimenez; Barbara White Journal: Am J Respir Cell Mol Biol Date: 2003-06-12 Impact factor: 6.914
Authors: Dominik Hartl; Rabindra Tirouvanziam; Julie Laval; Catherine M Greene; David Habiel; Lokesh Sharma; Ali Önder Yildirim; Charles S Dela Cruz; Cory M Hogaboam Journal: J Innate Immun Date: 2018-02-13 Impact factor: 7.349
Authors: Maya R Karta; Lisa E Wickert; Colleen S Curran; Monica L Gavala; Loren C Denlinger; James E Gern; Paul J Bertics Journal: J Allergy Clin Immunol Date: 2014-02-14 Impact factor: 10.793
Authors: Julia Kzhyshkowska; Alexandru Gudima; Kondaiah Moganti; Alexei Gratchev; Alexander Orekhov Journal: Transfus Med Hemother Date: 2016-03-15 Impact factor: 3.747
Authors: Marina Miller; Stephane Esnault; Richard C Kurten; Elizabeth A Kelly; Andrew Beppu; Sudipta Das; Peter Rosenthal; Joe Ramsdell; Michael Croft; Bruce Zuraw; Nizar Jarjour; Qutayba Hamid; David H Broide Journal: J Allergy Clin Immunol Date: 2016-04-20 Impact factor: 10.793
Authors: Jose L Gomez; Xiting Yan; Carole T Holm; Nicole Grant; Qing Liu; Lauren Cohn; Vera Nezgovorova; Deborah A Meyers; Eugene R Bleecker; Gina M Crisafi; Nizar N Jarjour; Linda Rogers; Joan Reibman; Geoffrey L Chupp Journal: Eur Respir J Date: 2017-10-12 Impact factor: 16.671
Authors: Ines Mack; Andreas Hector; Marlene Ballbach; Julius Kohlhäufl; Katharina J Fuchs; Alexander Weber; Marcus A Mall; Dominik Hartl Journal: Mol Cell Pediatr Date: 2015-02-27